[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350605-105":59,"doc-detail-350605-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","evolution-of-clonal-hematopoiesis-during-cancer-treatment-and-its-impact-on-outcomes","Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes","","Clonal hematopoiesis (CH) represents the age-related expansion of mutated hematopoietic stem cells without overt blood disorders. In patients with solid tumors, CH correlates with higher mortality and can progress to therapy-related myeloid neoplasms, though how treatment reshapes CH dynamics remains unclear. Analyzing 392 serial breast cancer samples, cytotoxic therapy imposed therapeutic bottlenecks that reduced allelic populations and drove differential clonal selection, with positively selected CH linked to the worst progression-free and overall survival. Results were validated across independent cohorts.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evolution-of-clonal-hematopoiesis-during-cancer-treatment-and-its-impact-on-outcomes/350605/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evolution-of-clonal-hematopoiesis-during-cancer-treatment-and-its-impact-on-outcomes/350605.png","ImageObject",300,407,{"name":92,"@type":93},"Anna Hans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is clonal hematopoiesis (CH) and why is it clinically important in solid tumors?","Question",{"text":112,"@type":113},"CH is the expansion of hematopoietic stem cells carrying somatic alterations without hematologic abnormalities. In solid tumors, it is associated with higher mortality and can evolve to therapy-related myeloid neoplasms.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the study evaluate the effect of cancer therapy on CH dynamics?",{"text":117,"@type":113},"The study analyzed 392 serial peripheral blood samples from breast cancer patients collected before, during, and after treatment. It quantified treatment-specific selective pressures, clonal fitness, and effective hematopoietic cell population sizes, and linked CH dynamics to clinical outcomes.",{"name":119,"@type":110,"acceptedAnswer":120},"Which CH changes during treatment were linked to worse survival?",{"text":121,"@type":113},"Positively selected CH that expanded through dose-dependent therapeutic bottlenecks was associated with mutations including TP53 and PPM1D, and patients with such CH had the shortest progression-free and overall survival compared with unchanging or negatively selected CH.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350605,1790165251,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},5909892332657,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","The Journal of Clinical Investigation RESEAR CH ARTICLE  \nEvolution of clonal hematopoiesis during cancer treatment and its impact on outcomes  \nMona Arabzadeh,1,2 Yi-Han Tang,3,4 Christelle Colin-Leitzinger,3 Sadegh Marzban,5 Daniel Walgenbach,6 Stefania Morganti,7,8 Vaidhyanathan Mahaganapathy,1 Erika Harper,9 Mingxiang Teng,4 Jacob K. Kresovich,3 Iman Washington,10 Heather A. Parsons,7,8 Judy E. Garber,7,8 Jeffrey West,5 Shridar Ganesan,1,11 Hossein Khiabanian,1,12 and Nancy Gillis3,13  \n1Center for Systems and Computational Biology, and 2Center for Biomedical Informatics, Bioinformatics Department, Rutgers Cancer Institute, Rutgers University, New Brunswick, New Jersey, USA. 3Department of Cancer Epidemiology, 4 Department of Biostatistics and Bioinformatics, and 5Department of Integrated Mathematical Oncology, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. 6Department of Internal Medicine, University of South Florida, Tampa, Florida, USA. 7Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 8Harvard Medical School, Boston, Massachusetts, USA. 9Department of Pathology, and 10Department of Radiation Oncology, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. 11Department of Medicine, Center for Molecular Oncology, NYU Perlmutter Cancer Center, New York, New York, USA. 12Department of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey, USA. 13Department of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.  \nClonal hematopoiesis (CH) is the age-related expansion of mutated hematopoietic stem cells without hematologic abnormalities. In patients with solid tumors, CH is associated with higher mortality and may evolve to therapy-related myeloid neoplasms; however, the mechanisms by which cancer treatments promote CH dynamics remain largely unknown. Here, we analyzed 392 serial samples from a prospective cohort of patients with breast cancer and show that cytotoxic treatments led to strong therapeutic bottlenecks, resulting in significant reductions in hematopoietic allelic populations and differential clonal selection. Positively selected CH that expanded through dose-dependent therapeutic bottlenecks harbored mutations in TP53, PPM1D, SRCAP, DNMT3A, and YLPM1. Patients with positively selected CH during treatment had the shortest progression-free and overall survival compared with patients with unchanging or negatively selected CH across all therapies. These findings, validated in independent breast cancer and pan-cancer cohorts, provide strong evidence for the clinical relevance of monitoring CH during cancer treatment.  \nIntroduction  \nClonal hematopoiesis (CH) is caused by the expansion of hematopoietic stem cells that carry somatic alterations in genes recurrently mutated in myeloid neoplasms. CH mutations with variant allele frequencies (VAFs) of 2% or higher, defined as clonal hematopoiesis of indeterminate potential (CHIP), are associated with increased overall mortality, cardiovascular disease, and progression to hematologic neoplasms (1–4) . CH mutations are more common in individuals with solid tumors compared with healthy population-based cohorts (5) and are routinely detected in blood and tumor specimens (6–8) .  \nThe growth pattern and Darwinian evolution of mutationdriven CH resemble cancer and are shaped by gene-specific fitness effects, hematopoietic cell–specific rates of mutation, and imposed adaptive pressure on hematopoiesis (9–14) . Cross-sectional studies have demonstrated a higher prevalence of CH mutations, particularly at CHIP-defining levels, following exposure to cancer therapy (15) . Longitudinal studies in cancer-free populations and patients with solid tumors have further shown mutation-specific CH evolution and progression to myeloid malignancies (16–20) . Analyses in  \nCopyright: © 2026, Arabzadeh et al. This is","cbCaikfrfw81HNg9","https://ap.wps.com/l/cbCaikfrfw81HNg9","pdf",5313235,16,"English","# Introduction\n## Clonal hematopoiesis definition and clinical associations\n## Evolutionary mechanisms and therapy-induced selection pressures\n# Results\n## CH mutational spectrum at breast cancer diagnosis","[{\"question\":\"What is clonal hematopoiesis (CH) and why is it clinically important in solid tumors?\",\"answer\":\"CH is the expansion of hematopoietic stem cells carrying somatic alterations without hematologic abnormalities. In solid tumors, it is associated with higher mortality and can evolve to therapy-related myeloid neoplasms.\"},{\"question\":\"How did the study evaluate the effect of cancer therapy on CH dynamics?\",\"answer\":\"The study analyzed 392 serial peripheral blood samples from breast cancer patients collected before, during, and after treatment. It quantified treatment-specific selective pressures, clonal fitness, and effective hematopoietic cell population sizes, and linked CH dynamics to clinical outcomes.\"},{\"question\":\"Which CH changes during treatment were linked to worse survival?\",\"answer\":\"Positively selected CH that expanded through dose-dependent therapeutic bottlenecks was associated with mutations including TP53 and PPM1D, and patients with such CH had the shortest progression-free and overall survival compared with unchanging or negatively selected CH.\"}]","Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes | PDF",1790089852,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81e6b2b26205b1f3e1ad568d30d069c2.webp",983,1315,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7822021a4b5b9e2420318368e8f176b8.webp",982,1314,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4ed4830c8e3a36421e9a322c188f0ef.webp",981,1312,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5fab195fbec00ddaa56774511c10e64.webp",980,1311]